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Summary The bcl-2 gene is overexpressed in the absence of gene rearrangements in most cases of B-cell chronic lymphocytic leukaemia
(B-CLL) and the proto-oncogene product Bc1-2 has been shown to be a regulator of apoptosis. The activity of this protein is opposed by Bax,
a homologous protein that accelerates the rate of cell death. B-lymphocyte Bcl-2 and Bax protein levels were found to be significantly altered
in B-CLL and increased Bcl-2/Bax ratios were observed in both the treated and untreated patients compared with those of normal controls.
These alterations were particularly pronounced in those treated patients found to be clinically unresponsive to chemotherapy. In order to
determine whether Bcl-2/Bax ratios affected cell survival via an anti-apoptotic mechanism, cell death was induced in B-CLL cells in vitro using
chlorambucil, and apoptosis was monitored by Annexin V and propidium iodide staining. Confirmation that the labelled cells were apoptotic
was achieved by morphological assessment of cytospin preparations of cell-sorted populations. Drug-induced apoptosis in B-CLL cells was
inversely related to Bcl-2/Bax ratios.
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B-cell chronic lymphocytic leukaemia (B-CLL) is characterized
by the accumulation in the blood, bone marrow, lymph nodes and
spleen of a clonal population of non-dividing, usually CD5+, B-
lymphoctyes that weakly express surface immunoglobulin and
surface markers of B-cell differentiation (CD19, CD20 and
CD40). The clonal expansion appears to be due to the extended
survival ofresting monoclonal B-cells rather than to an increase in
their proliferative activity. Despite a long half-life in vivo, B-CLL
cells typically undergo rapid apoptosis during short-term culture
(Robertson and Plunkett, 1993).
It has been suggested for several years that the bcl-2 family of
proto-oncogenes plays a central role in the development ofcertain
malignancies, including B-CLL. Bcl-2 protein has been consis-
tently found to be up-regulated in B-CLL and is thought to be
involved in an anti-apoptotic mechanism that facilitates B-CLL
cell survival (Gottardi et al, 1995). However, recent reports have
shown thatthe dysregulation ofBax, an antagonistic homologue of
Bcl-2, may in fact be more crucial to the maintenance of this
condition (Pepper et al, 1996; Thomas et al, 1996). In any event it
would appear that the Bcl-2/Bax ratio may be of primary impor-
tance when determining whether cells are resistant or sensitive to
treatment. As most chemotherapeutic drugs exert their cell killing
effect through the induction ofapoptosis, it seems likely that Bcl-2
and Bax influence the ability of cells to undergo apoptotic cell
death (Reed, 1995). This present study was designed to examine
the relationship between Bcl-2/Bax ratios, clinical resistance and
in vitro apoptosis in patients with B-CLL.
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MATERIALS AND METHODS
Patients, cell isolation and incubation conditions
Peripheral blood was obtained from 22 B-CLL patients after
informed consent was obtained. Clinical responsiveness was
assessed in accordance with the National Cancer Institute Working
Group Guidelines (Cheson et al, 1988), and clinical staging was
based on the Binet system (Binet et al, 1981). All previously
treated patients had received chlorambucil therapy and four were
defined as refractory based on failure to meet standard response
criteria (Cheson et al, 1988).
Peripheral blood lymphocytes were isolated by density centrifu-
gation on Ficoll-Hypaque (Sigma, UK) and were washed three
times in phosphate-buffered saline (PBS). Aliquots ofthe lympho-
cytes to be cultured were then resuspended in Eagle medium
(Gibco, UK) at aconcentration of 1x106 cells ml-1 and incubated at
37°C in a 5% carbon dioxide atmosphere for 48 h.
Bcl-2 and Bax analysis
Separated peripheral blood lymphocytes were analysed by triple-
colour immunofluorescent staining forbcl-2, bax andCD19 (pan-B-
cell marker). Approximately 1x106 cells were incubated with 10 ,ul
of anti-CD19 Cy5 PE-conjugated antibody or an isotype-negative
control (DAKO, UK). The cells were then fixed using a commer-
cially available kit, 'Fix & Perm' (Caltag, USA), washed in PBS
and centrifuged at 300g for 5 min. The pelleted cells were resus-
pended in permeabilization solution and incubated with 10l1 of
each antibody or isotype-negative control, i.e. Bcl-2 FITC (DAKO,
UK) and Bax (Santa Cruz, USA). The cells were washed again and
incubated with a PE-labelled secondary antibody for the Bax-
stained cells (Serotec, UK). Finally, the cells were washed,
centrifuged at 300 g for 5 min and resuspended in 0.5 ml of 1%
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Figure 1 Bcl-2/Bax ratios for treated and untreated B-CLL patients. Treated
patients (lanes 1-10) and untreated patients (lanes 11-22). Approximately
1 X 106 cells were incubated with anti-Bcl-2 and anti-Bax antibodies, and the
Bcl-2 and Bax expression was determined by flow cytometric analysis
paraformaldehyde before flow cytometric analysis. All samples
were analysedusing aFACScan flow cytometer (BectonDickinson)
with LYSYS II software. From each sample, 10 000 cells were
analysed and non-specific binding was excluded by gating around
the isotype-negative control antibodies. The CD19-positive B-cells
were also gated before analysis ofBcl-2 and Bax staining to ensure
that only B-lymphocytes were measured. Calibration of the data
was achieved by monitoring amixture ofbeads labelled with known
amounts of fluorochrome (Dako, UK), which enabled results to be
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expressed in units of fluorochrome detected, i.e. molecules
equivalent soluble fluorochrome (MESF).
Measurement of in vitroapoptosis
Cells were cultured as described previously and were rendei
apoptotic by using chlorambucil at doses of 1, 2, 3 and 5 ,ug m
Spontaneous apoptosis was measured in cultured cells that w
notexposed to drug. Double-staining for FITC-Annexin V bind:
and for cellular DNA using propidium iodide (PI) was perfom
as follows. After washing three times in PBS, the cultured c(
were resuspended in binding buffer (10 mM Hepes/sodii
hydroxide, pH 7.4, 140 mM sodium chloride, 2.5 mm calcil
chloride). FITC-Annexin V was added to a final concentration
1 jg ml-' and the cells were incubated in the dark for 10 min. 1
cells were then washed again in PBS, centrifuged at 300g g
resuspended in binding buffer (100 ,ul). Before flow cytomel
analysis 10gl of PI (10 jig ml-' in binding buffer) was added
each sample. Confirmation that the labelled cells were apoptc
was achieved by morphological assessment of cytospin prepa
tions ofcell-sorted populations.
Statistical analysis
The data obtained in these experiments were evaluated using
Student's t-test and correlation coefficients were calculated fri
least-squares linear regression plots.
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Figure 2 The progressive increase of apoptotic cell death after incubation for 48 h with increasing chlorambucil concentrations as measured by Annexin
V-FITC labelling. These data can be used to determine the ID50 for each patient
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RESULTS
Bcl-2 and Bax protein expression
Bcl-2 and Bax protein expression was determined by triple-colour
immunofluorescence of peripheral blood lymphocyte samples
from 22 B-CLL patients using flow cytometry. The results were
expressed as MESF of the antibody staining and were compared
with levels of Bcl-2 and Bax protein determined previously in
peripheral blood B-lymphocytes from healthy donors (Pepper et
al, 1996). The MESF for both Bcl-2 and Bax for each patient were
then used to calculate the Bcl-2/Bax ratio (Figure 1).
Bcl-2/bax ratios and in vivo responsiveness
The ten treated patients were assessed for Bcl-2 and Bax protein
expression in this present study. Four had been defined as refrac-
tory, based on failure to meet standard response criteria. All of
these patients had elevated Bcl-2/Bax ratios, suggesting that Bcl-
2/Bax ratios may be a useful prognostic indicator for chemoresis-
tance. In addition, the untreated patients exhibited a wide range of
Bcl-2/Bax ratios, some of which were within the normal control
range established previously (Pepper et al, 1996). It may be that
these patients represent a subset of B-CLL patients whose disease
has greater sensitivity to chemotherapy.
Measurement of in vitro apoptosis
Apoptotic cells exclude all those dyes that are in use for cell
viability assays, such as PI, while necrotic cells do not. However,
late-stage apoptotic cells also undergo cell membrane damage in
vitro and so these cells will also stain positive for PI. This finding
was confirmed by analysis of cell-sorted fractions of the 'double-
positive' cells in the form of cytospins. Characteristic apoptotic
bodies were observed together with increased granularity and a
markedly shrunken appearance (not shown). Figure 2 shows the
results of bivariate FITC-Annexin V/PI flow cytometry of B-CLL
cells after incubation with chlorambucil for 48 h. The lower left
quadrant ofthe histograms shows the viable cells, which exclude PI
and are negative for FITC-Annexin V binding. The lower right
quadrant represents the early apoptotic cells, which are PI negative
and Annexin V positive, indicating the translocation of phos-
phatidyl serine to the extermal cell surface but integrity ofthe cyto-
plasmic membrane (Vermes et al, 1995). The upper right quadrant
represents the non-viable necrotic and late-stage apoptotic cells,
which are positive for Annexin V binding and PI uptake. The
number of apoptotic and necrotic cells increased with increasing
drugconcentration, andID50values were calculated byplotting drug
concentration against log ofpercentage viable cells. Figure 3 shows
ID values and Bcl-2/Bax ratios oftreated and untreated patients.
Correlation of Bcl-2/Bax ratios and ID0 values
Although Bcl-2 and Bax protein expression varied within the
treated and untreated groups, there was correlation between Bcl-2
andID50values (r = 0.8310) and Bax andID50 values (r =-0.6129).
When the Bcl-2/Bax ratios were correlated with chlorambucil ID50
values, a significantly higher correlation coefficient was obtained
(r = 0.9702). This would indicate that the combined ratio ofthe two
proteins is more significant in determining the in vitro response to
chemotherapy than the individual proteins alone (P = 0.0001).
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Figure 3 Chlorambucil ID., values and corresponding Bcl-2/Bax ratios for
treated and untreated B-CLL patients. Treated patients (lanes 1-10) and
untreated patients (lanes 11-22)
DISCUSSION
Although B-CLL cells show a decreased ability to proliferate
compared with normal B-cells, they have a longer lifespan in vivo,
which serves to maintain the tumour cell population. In contrast,
when these cells are cultured in vitro, a significant proportion of
the cells die by apoptosis (Collins et al, 1989). Incubation with
cytotoxic drugs, such as chlorambucil, accelerates this process
(Begleiter et al, 1994). The mechanism for the induction of apop-
tosis by these agents is yet to be determined but it seems likely that
Bc1-2 and Bax proteins play important roles in determining
whether cells undergo apoptosis (Oltvai et al, 1993; Reed, 1995).
Dysregulation of the Bcl-2 gene was first demonstrated in follic-
ular lymphomas as a result of t(l4, 18) translocations. Although
Bcl-2 gene rearrangements are unusual in B-CLL, high levels of
Bc1-2 proteins expression have been consistently reported (Hanada
et al, 1993; Thomas et al, 1996). Robertson et al (1996) found that
25 of 44 cases (57%) had Bc1-2 expression higher than that
measured in peripheral blood lymphocytes. These present data
show 14 of 22 cases (64%) with elevated Bc1-2 expression.
Perhaps of more significance is the finding that 19 of 22 cases
(86%) were found to express levels of Bax protein lower than
those found in normal peripheral blood lymphocytes.
Previous work has indicated that B-CLL cells undergo apoptosis
more readily in patients with untreated, early-stage disease
(Robertson and Plunkett 1993). Recently Thomas et al (1996) eval-
uated B-CLL cells, using a semi-quantitative method, for their
apoptotic response to drug treatment in vitro and found that cells
with a high bcl-2fbax ratio were more drug resistant than cells with
a low bcl-2/bax ratio. Our current data show a trend towards an
apoptosis-resistant phenotype with treatment, but it remains unclear
as to whether this is due to selection of a resistant population or
induction of drug resistance. In addition, we have shown that Bcl-
2/Bax ratios correlate with ID50 values (as measured by in vitro
apoptotic cell death) and also clinical responsiveness. Therefore, it
would appear that measurement of Bcl-2JBax ratios and in vitro
apoptosis may be of prognostic value for determining whether a
patient might be clinically resistant to cytotoxic chemotherapy.
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